Quantitative competitive RT-PCR techniques have been developed to detect BCR-ABL fusion transcripts in CML but they are hardly reproducible. In this work, we have developed BCR-ABL quantification by real time RT-PCR using the ABI PRISM 7700 (Perkin Elmer), a new technique which allows simple and rapid quantification of a target sequence during the extension phase of PCR amplifications. A fluorogenic probe labeled with both a reporter dye at the 5Ј end and a quencherdye at the 3Ј end hybridizes to the target sequence on the third exon of the ABL gene. The exonuclease activity of the Taq DNA polymerase cleaves the probe and releases the reporter dye, resulting in an increase in the fluorescence signal. The absolute copy number of the target sequence (BCR-ABL) or a control gene (ABL) in an unknown sample can then be calculated using a calibration curve prepared from a set of BCR-ABL RNA standards, and results are expressed as a BCR-ABL/ABL ratio. In our hands, the sensitivity of a serial dilution of total RNA from a positive cell line (K562) in a negative cell line (HL60) was 10 −4 . Fifteen CML patients in cytogenetic CR, including 11 allografted patients, two autografted patients and two patients treated by IFN were studied sequentially by this new real time quantitative RT-PCR technique in parallel with conventional qualitative two round nested RT-PCR. The two autografted patients showed high BCR-ABL/ABL ratio in all samples. The two patients treated by IFN showed a progressive decrease in the ratio. In the 11 allografted patients, four were sequentially studied 2 years or more after allo-BMT, and all ratios were below 10 
Introduction
Chronic myelogenous leukemia (CML) is characterized, in more than 95% of the cases, by a t(9;22) translocation (Philadelphia (Ph) chromosome) between the ABL protooncogene on chromosome 9 and the BCR gene on chromosome 22. 1, 2 More than 99% of the cases of Ph-positive CML express a BCR-ABL chimeric mRNA in which either the exon 2 (b 2 a 2 junction) or the exon 3 (b 3 a 2 junction) of the major breakpoint cluster region of the BCR gene are spliced to exon 2 of the ABL gene. Amplification of the chimeric BCR-ABL mRNA by the reverse/transcription polymerase chain reaction (RT-PCR) is a very sensitive technique for the detection of minimal residual disease after treatment in CML. 3, 4 A large number of minimal residual disease studies in CML, [5] [6] [7] [8] [9] [10] including by our group, have confirmed the high risk of relapse associated with late positive results. However, this qualitative technique is often considered to have little predictability in individual patients. [7] [8] [9] [10] Furthermore, qualitative RT-PCR is not adapted to the follow-up of residual disease during the first 6 months after allogeneic bone marrow transplantation (alloBMT) or interferon (IFN) treatment. For these reasons, some groups have developed quantitative competitive techniques. [11] [12] [13] [14] However, most of those techniques did not give linear results for more than two logs, induced a high probability of contamination, were quantitative only when used with a competitor carrying minor modification, were time-consuming because they required laborious post-PCR processing steps, and finally constituted an end-point quantification.
In this work, we have developed BCR-ABL quantification by one step real-time RT-PCR using the ABI Prism 7700 (Perkin Elmer, Foster City, CA, USA), a new technique which allows simple and rapid quantification of a target sequence during the exponential phase of PCR amplifications. 15, 16 The approach uses dual labeled fluorogeneic hybridization probes, where one fluorescent dye serves as a reporter (FAM (ie 6-carboxyfluoresceine)) and its emission spectrum is quenched by the second fluorescent dye, TAMRA (ie 6 carboxy-tetramethyl-rhodamine). The exonuclease activity of the Taq polymerase cleaves the probe and releases the reporter dye, resulting in an increase in the fluorescence signal. 17 Only two reports on this approach in hematological malignancies have been recently published. 18, 19 In both reports, the technique was performed in two steps: one RT and one PCR step. We report here the quantification of minimal residual disease using a single tube for RT and PCR reaction and use RNA as an initial template in 15 CML patients who received different treatments, and its correlation with standard qualitative RT-PCR clinical and cytogenetic data.
Patients and methods
Fifteen patients with Ph chromosome positive CML diagnosed at our institution (Centre Hospitalier Universitaire of Lille, France) were included in this study. Eleven of them (patients Nos 1 to 11, Table 1 ) were treated by allogeneic bone marrow 
Cytogenetic analysis
Cytogenetic analysis was performed on bone marrow cells at diagnosis and during evolution, after 24 h in vitro culture without stimulation. Chromosomes were identified by RHG and GTG banding. At least 100 mitoses were analyzed before deciding on the absence of Ph Chromosome.
RT-PCR analysis Extraction of RNA:
RT-PCR analysis was performed on RNA obtained from circulating leukocytes after informed con-sent, from a positive (K562) and a negative (HL60) cell line, respectively. Cells lines were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) RNA was extracted using the commercial kit (TRIZOL, Life Technologies, Cergy Pontoise, France) based on a standard procedure. 18 The quality of each RNA was controlled on a 0.8% agarose gel stained by ethidium bromide.
Real time quantitative RT-PCR procedure:
RT-PCR conditions: For this analysis, we used one step RT-PCR procedure according to the manufacturer's recommendations (Perkin Elmer). 200 ng of total RNA was mixed with 10 mm Tris HCl, 50 mm KCl, 2 to 7 mm MgCl 2 , 1 mm dithiothreitol (DTT), 300 pmol dATP, dCTP dGTP, 600 pmol dUTP, 5 to 200 pmol of each primer (ABL A and ABL B for the ABL transcript (Table  1) , ABL A and BCR A for the BCR-ABL transcripts) ( Table 2 ), 5 to 20 pmol of the labeled probe, 12.5 U of MMLV reverse transcriptase (Perkin Elmer), 20 U of RNase inhibitor (Perkin Elmer) and 1.25 U of Taq Polymerase (Amplitaq GOLD; Perkin Elmer). Reverse/transcription was performed at 48°C for 30 min followed by PCR amplification including a first step of 10 min at 95°C followed by 40 cycles of amplications (95°C for 15 s and 60°C for 90 s). All experiments were performed in duplicate. After amplification, the size of product was 201 bp for ABL transcript, 257 bp for b2a2 and 332 bp for b3a2 BCR-ABL transcript. The choice of primers and probe was defined using the primer express software (Perkin Elmer).
Analysis and expression of the data:
The quantification of the starting copy number in an unknown sample was performed by preparing a standard curve using serial dilutions of a known amount of standard RNA. For each sample, the AbiPrism 7700 software provided an amplification curve constructed by relating the fluorescence signal intensity (⌬Rn) to the cycle number. The ⌬Rn value corresponded to the variation in the reporter fluorescence intensity before and after PCR, normalized to the fluorescence of an internal passive reference.
Cycle threshold (C t ) was defined as the cycle number at which a significant increase in the fluorescence signal was first detected (the higher the starting copy number, the lower the C t ). Using serial dilutions of a standard RNA, the standard curve was then generated on the basis of the linear relationship existing between the C t value and the logarithm of the starting copy number. The quantification in the unknown samples was then performed by the software which calculated the C t values for each sample and used the standard curve to determine the initial copy number of target for each sample.
The absolute copy number of a target sequence (BCR-ABL) or control gene (ABL) in an unknown sample was calculated using a fluorescence curve prepared from a set of BCR-ABL RNA standards, ranging from 0.056 to 560 pg obtained after in vitro reverse transcription of a cloned BCR-ABL (b3a2) frag- Table 2 Name and sequence of primers and probe used for real time quantification
Name Sequence ABL A 5ЈgTgATTATAgCCTAAgACCCgg3Ј ABL B 5ЈCTTCAgCggCCAgTAgCATCT3Ј BCR A 5ЈCgTgTgTgAAACTCCAgACTgTCCA3Ј Probe 5ЈTTCACCTTTAgTTATgCTTAgAgTgTTATCTCCAC3Ј ment in a bluescript plasmid (generous gift of B Grandchamp, Faculté Bichat, Paris, France). The size of the BCR-ABL fragment was 420 bp and it contained the totality or part of exons b2, b3 of the BCR gene and a2 and a3 of the ABL gene: 1 pg of the RNA obtained after in vitro reverse transcription corresponded to 3.64 × 10 5 copies of BCR-ABL or ABL gene. For each sample, the quantity of BCR-ABL transcript was normalized to the absolute quantity of the ABL gene transcript, and the result was expressed as the number of BCR-ABL copies/ABL copy.
Conventional RT-PCR:
All RNA samples tested by the realtime procedure were tested in parallel by conventional RT-PCR protocol, using previously published methods. 5 Briefly, after reverse transcription, the cDNA was amplified using a nested PCR technique. After amplification, 7 l of the PCR products were run on a 2% agarose gel stained with ethidium bromide and photographed. The sensitivity of the assay was 10 −4 after one round of PCR, and 10 −6 after two round of PCR in our hands.
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Results
Optimization of the real-time quantitative RT-PCR procedure
The parameters influencing the quantification were MgCl 2 , probe and primer concentrations. For each parameter, the optimum concentration was determined to achieve the best compromise between a high ⌬Rn value and a low C t value. The final procedure was performed using 20 pmol of each primers, 10 pmoles of probe and 5 mm or 6 mm MgCl 2 for ABL and BCR-ABL, respectively.
Using these conditions, we obtained the results shown in Figure 1 , for BCR-ABL and ABL amplification, respectively. In our study, the slope values of the standard curves ranged between −3.71 and −3.33, corresponding to values of PCR efficiency ranging from 86% to 99%. Mean intra-assay variation of C t values, evaluated on six replicates of the same RNA (50 pg of RNA from K562 in 200 ng of RNA from HL60) were 0.3 (range 0.3 to 0.4) and 0.4% (range 0.2 to 0.5), respectively, for BCR-ABL or ABL. These standard deviations in the C t therefore reflected a 8% and 13% in the starting quantity of BCR-ABL and ABL gene respectively. Finally, in the final BCR-ABL/ABL ratio, the standard deviation was 12%.
Sensitivity
In order to study the sensitivity of our technique, we compared 10-fold dilutions of cells or total RNA from positive cell line K562 in negative cell line HL60. In our hands, no discrepancies were observed between the two dilution techniques (cells or RNA). The last dilution giving linear results was 10
corresponding to 20 pg of K562. The same result was observed with the BV173 cell line which has a b2a2 transcript. Beyond this dilution, points presented great discrepancies and results were not reproducible. The quality of RNA was also assessed, using quantification of a housekeeping gene (ie the ABL gene). All samples having less than 560 pg of ABL transcripts number (ie the first dilution) were excluded for quantification. The sensitivity of the assay could therefore be considered as one copy of BCR-ABL for 10 −4 copies of ABL.
RT-PCR results in CML patients
Patients who received allo-BMT (patient Nos 1 to 11):
In patient Nos 1 to 4, the sequential follow-up study was started 2 to 4 years after allo-BMT. All samples, taken 24 to 96 months after allo-BMT, were negative by two round conventional RT-PCR, and had a BCR-ABL/ABL ratio below 10 −4 by real-time quantitative RT-PCR.
Patient Nos 5 to 7 were sequentially studied starting just before and until 30 months after allo-BMT. By conventional RT-PCR, positive results after the first round were obtained before BMT, positive results were obtained after the second or the first round within 7 months of allo-BMT, and negative results were obtained after two rounds beyond 7 months in the three patients. By real-time quantitative RT-PCR, we observed a rapid decrease of the ratio after allo-BMT in patient 5, to less than 10 −4 after 2 months and in all subsequent analyses. In patients 6 and 7, the decrease of the ratio was slower, but the BCR-ABL/ABL ratio became less than 10 −4 after 14 months in patient 7. Patients 1 to 7 remained in hematological and cytogenetic remission.
Patients 8 to 10 had, by conventional RT-PCR, a positive result after the first round in all the samples studied. By realtime quantitative RT-PCR, a ratio greater than 10 −3 was observed in all the samples and it increased with time in the three patients. All three patients had hematological and cytogenetic relapse 11, 9 and 38 months after allo-BMT and 3, 3 and 22 months after the ratio started to increase. After relapse, patients 9 and 10 received donor leukocyte infusions (DLI). Four months after DLI, patient 9 had positive RT-PCR after the first round by conventional RT-PCR, and a BCR-ABL/ABL ratio of 10 −2 by real-time quantitative RT-PCR. No cytogenetic and hematological remission was observed and this patient died 1 year later. In patient 10, the first four samples taken after DLI were positive after one round by conventional RT-PCR, the next sample after the second round and the last sample were negative. By real-time quantification, we observed a rapid decrease of the BCR-ABL/ABL ratio from 0.096 to less than 10 −4 . This patient achieved hematological and cytogenetic remission 4 months after DLI, but he died 10 months later of myocardial infarction.
Patient 11 was studied sequentially between 16 and 71 months after allo-BMT. By conventional RT-PCR, negative results were found in the samples obtained between 16 and 60 months. A positive result was observed after the second round at 65 months and positive results after the first round after 70 and 71 months. Within 60 months of the transplantation, a BCR-ABL/ABL ratio lower than 10 −4 was observed by real-time quantificative RT-PCR and after 60 months, we observed a slow increase of the BCR-ABL/ABL ratio, to 0.0013, 0.0122 and 0.0372, respectively. The patient developed cranial granulocytic sarcoma 70 months after allo-
Figure 2
Comparison between real-time quantitative RT-PCR and conventional qualitative two round nested RT-PCR in the 15 CML patients. DLI, donor lymphocyte infusions.
BMT, without hematological or cytogenetic evidence of marrow relapse.
Patients who received autologous peripheral stem cell transplantation auto-PBSC (patients 12 and 13):
After autologous PBSC, both patients achieved hematological CR. By conventional RT-PCR, all samples were positive after the first round and by real-time quantitative RT-PCR, all samples had a high BCR-ABL/ABL ratio. Patient 12 was still in hematological and cytogenetic remission. Patient 13 had a cytogenetic relapse followed by a hematological relapse, 80 months and 90 months after diagnosis, respectively.
Patient treated by interferon (patients 14 and 15):
In patient 14, RT-PCR was performed on four occasions, 1, 3, 13 and 20 months after the onset of treatment. By conventional RT-PCR, the first three samples were positive after the first round and the last sample after the second round. By realtime quantitative RT-PCR, a slow decrease of the BCR-ABL/ABL ratio was observed: 0.98, 0.097, 0.0037 and less than 10 −4 after 1, 3, 13 and 20 months, respectively. Cytogenetic remission was obtained 7 months after the onset of treatment and was persisting 20 months after the onset of IFN.
In patient 15, RT-PCR was performed on three occasions, 13, 20 and 36 months after the onset of treatment. By conventional RT-PCR, a positive result after the second round was observed after 13 months, a negative result after the second round after 20 months and a positive result after the second round at 36 months. By real-time quantitative RT-PCR, BCR-ABL/ABL ratios of 0.0025, less than 10 −4 and 0.0005 were obtained after 13, 20 and 36 months, respectively. Cytogenetic remission was obtained after 8 months and was persisting 36 months after the onset of IFN.
Discussion
It is generally agreed that, in allografted CML patients, positive PCR results in the 6 months post-transplant are not an indi-
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Continued cator of later relapse if PCR results subsequently become negative. [7] [8] [9] [10] The prognostic value of qualitative PCR results more than 6 to 9 months after non-T cell-depleted allo-BMT or after IFN treatment is more controversial and qualitative PCR is often considered to have little predictability in individual patients. In this work, we compared our classical qualitative RT-PCR technique with a 'real time' quantitative RT-PCR assay.
Unlike Mensink et al 18 we used a technique where RT and PCR are performed in one single tube. This technique reduces the risk of contamination, is less time-consuming and uses as standard the same target as in the patients (RNA and not DNA). However, although the two technique were different, their sensitivity was similar (10 pg of K562 for Mensink et al, 20 pg for our technique).
In in samples with negative conventional RT-PCR. Furthermore, the lower sensitivity of the real-time quantitative RT-PCR technique was counterbalanced by the fact that this technique allowed a better kinetic analysis of BCR-ABL transcript level than conventional nested RT-PCR. For example, in patient 11, a steep increase of the signal by real-time quantitative RT-PCR was observed 5 months before extramedullary relapse, whereas conventional RT-PCR switched from negative to positive after two rounds only 5 months before relapse. In patient 9, conventional RT-PCR was positive after one round, 6 and 8 months from allo-BMT, a result which was difficult to interpret. At the same time, real-time quantitative RT-PCR showed increasing ratios, which were followed 3 months later by hem-atological relapse. By contrast, in patient 7, by real-time quantitative RT-PCR the ratios continued to decrease after 5 months post-allo-BMT; conventional RT-PCR only subsequently switched from positive after one round to positive after the second round, and no relapse occurred. In patient 14 treated by IFN, a progressive decrease in the ratio preceded the switch from first-round to second-round positive conventional PCR results. Real-time quantitative RT-PCR was also interesting after DLI (patients 9 and 10): a rapid ratio decrease (patient 9) was followed by complete hematological and cytogenetic remission achievement whereas a very slow decrease (patient 10) was associated with lack of clinical response. In all these cases, real-time quantitative RT-PCR was well correlated to clinical evolution and appeared to give earlier prediction of clinical outcome than the classical nested PCR. Evolution of the real-time quantitative RT-PCR ratio could thus help clinicians in making treatment decisions before cytogenetic or hematological relapse. This would be important, because for example several studies have suggested good correlation, in patients relapsing after allo-BMT in CML, between molecular reponse after DLI and precocity of treatment. 20 In our hands, this real-time quantitative RT-PCR technique was reproducible, as the coefficient of variation in duplicate tests for the same sample was less than 1% in the C t . Furthermore, it is currently the only routinely available technique providing true quantification of target RNA or DNA. Indeed, PCR reactions develop in an exponential phase, followed by a plateau phase. Among previously published quantitative methods, some compared the quantity of PCR product obtained at the plateau phase in the tested samples with those obtained by serial dilutions of a standard. However, the plateau level obtained after PCR can vary substantially, depending on a relatively large number of variables. By contrast, the real-time quantitative RT-PCR procedure evaluates the quantity of PCR products at the onset of the exponential phase, where this quantity is directly proportional to the initial amount of target. The other quantitative techniques using competitive PCR where the tested sample is amplified in parallel with a mutated standard give more adequate results but are difficult to apply routinely and are time-consuming. [11] [12] [13] [14] In conclusion, real-time quantitative RT-PCR is easy, reproducible and rapid and appears to be useful for the follow-up of minimal residual disease in CML patients. This assay should further improve the current methods of detection of minimal residual disease, and help make early treatment decisions. Finally, we and others are currently applying it to the quantification of minimal residual disease in other hematological malignancies characterized by fusion transcripts such as AML with t(8;21), t(15;17) or inv (16) .
